Advanced in Inflammatory Breast Cancer

Dr. Roisin M. Connolly

Oncology

600 N Wolfe St,

Baltimore, MD

Advanced in Inflammatory Breast Cancer

600 N Wolfe St,

Baltimore, MD

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roisin Connolly is an Oncologist in Baltimore, Maryland. Dr. Connolly is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Tissue Biopsy.

Her clinical research consists of co-authoring 102 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MD

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Locations

600 N Wolfe St, Baltimore, MD 21287

Call: 410-955-1963

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Drug

Study Drugs: Capecitabine, Carboplatin, Cisplatin

Study Phase: Phase 3

A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases

Enrollment Status: Completed

Publish Date: January 23, 2026

Intervention Type: Drug, Procedure

Study Drugs: HKI-272, Capecitabine, Ado-Trastuzumab Emtansine

Study Phase: Phase 2

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 18, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate

Study Phase: Phase 3

A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 24, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Atezolizumab, Olaparib

Study Phase: Phase 2

A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

Enrollment Status: Active_not_recruiting

Publish Date: October 30, 2025

Intervention Type: Drug, Other

Study Drugs: Docetaxel, PI3Kbeta Inhibitor AZD8186

Study Phase: Phase 1

Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)

Enrollment Status: Active_not_recruiting

Publish Date: October 16, 2025

Intervention Type: Procedure, Drug

Study Drugs: carboplatin, paclitaxel, atezolizumab

Study Phase: Phase 2

A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: October 02, 2025

Intervention Type: Procedure, Other, Drug, Biological

Study Drugs: Entinostat, Ipilimumab, Nivolumab

Study Phase: Phase 1

A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab

Enrollment Status: Active_not_recruiting

Publish Date: July 02, 2025

Intervention Type: Drug

Study Drugs: Vinorelbine, Trastuzumab, Avelumab, Utomilumab

Study Phase: Phase 2

A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: July 01, 2025

Intervention Type: Drug, Procedure

Study Drugs: Trastuzumab, Pertuzumab

Study Phase: Phase 2

A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Enrollment Status: Completed

Publish Date: June 13, 2025

Intervention Type: Biological, Drug

Study Drugs: LGK974, PDR001

Study Phase: Phase 1

A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors

Enrollment Status: Completed

Publish Date: February 10, 2025

Intervention Type: Procedure, Drug, Other

Study Phase: Phase 1

A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction

Enrollment Status: Completed

Publish Date: February 07, 2025

Intervention Type: Drug, Other

Study Drug: Romidepsin

Study Phase: Phase 1

A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer

Enrollment Status: Completed

Publish Date: December 12, 2024

Intervention Type: Other, Drug

Study Drugs: atezolizumab, carboplatin

Study Phase: Phase 2

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

Enrollment Status: Completed

Publish Date: December 21, 2023

Intervention Type: Biological

Study Drugs: MGD013, MGD013+Margetuximab

Study Phase: Phase 1

View 14 Less Clinical Trials

104 Total Publications

EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).

Journal: Future oncology (London, England)

Published: October 06, 2025

View All 104 Publications

Similar Doctors

Distinguished in Inflammatory Breast Cancer

Dr. David A. Riseberg

Oncology | Hematology

Distinguished in Inflammatory Breast Cancer

Dr. David A. Riseberg

Oncology | Hematology

Lutherville Hematology And Oncology Services

1734 York Rd,

Lutherville, MD

(9.2 miles away)

410-494-9099

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

David Riseberg is an Oncologist and a Hematologist in Lutherville, Maryland. Dr. Riseberg is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer. Dr. Riseberg is currently accepting new patients.

Distinguished in Inflammatory Breast Cancer

Dr. Cesar A. Santa

Oncology

Distinguished in Inflammatory Breast Cancer

Dr. Cesar A. Santa

Oncology

Skip Viragh Outpatient Cancer Center

Baltimore, MD

(1.2 miles away)

410-955-8964

Languages Spoken:

English, Spanish

See accepted insurances

Offers Telehealth

Dr. Santa-Maria completed his oncology training at Johns Hopkins, and has been focused on caring for patients with breast cancer since then. He works as both a primary oncologist and consultant for patients with all types and stages of breast cancer. His research interest is in developing new types of treatment for patients with breast cancer using immunotherapy. Dr. Santa is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast.

Distinguished in Inflammatory Breast Cancer

Dr. Katherine H. Tkaczuk

Oncology

Distinguished in Inflammatory Breast Cancer

Dr. Katherine H. Tkaczuk

Oncology

University Of Maryland Oncology Associates PA

22 S Green St,

Baltimore, MD

(1.9 miles away)

410-328-1230

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Katherine Tkaczuk is an Oncologist in Baltimore, Maryland. Dr. Tkaczuk is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. Dr. Tkaczuk is currently accepting new patients.

VIEW MORE INFLAMMATORY BREAST CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Connolly's expertise for a condition

ConditionClose